10:59 AM EST - Arch Biopartners Inc. : Has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury. Arch Biopartners Inc.
shares V.ARCH are trading up $0.04 at $0.93.
